ERBB2 and breast carcinoma: On the other hand, the cytotoxicity studies indicate that the encapsulation of MZ1 in nanoparticles and ulterior conjugation with trastuzumab improved antitumoral effects in over-expressing HER2+ breast cancer cell lines, such as SKBR3 and BT474.